HUTCHMED (00013.HK): SYVIK Wins China NMPA Nod for Two Indications
NewTimeSpace News: On 19 November 2026, HUTCHMED (China) Limited (stock code: 00013.HK) said the China National Medical Products Administration (NMPA) granted simultaneous approval for two new drug applications of SYVIK (sovleplenib), a novel, selective oral spleen tyrosine kinase (Syk) inhibitor, for adult patients with chronic primary immune thrombocytopenia (ITP) who have had an insufficient response to at least one prior therapy, and for adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) who have had an insufficient response to prior corticosteroid therapy.
HUTCHMED described SYVIK as the first novel Syk inhibitor approved in China, adding that the approvals expand its commercial portfolio into immunology beyond oncology.
The ITP approval is supported by the ESLIM-01 Phase III trial in 188 adult patients in China, in which the durable response rate was 48.4% versus zero with placebo (p<0.0001); overall response rates were 68.3% at 0-12 weeks and 70.6% at 0-24 weeks, versus 14.5% and 16.1% with placebo. The wAIHA approval is based on the ESLIM-02 Phase II/III study, with a durable response rate of 66% versus 15% during weeks 5-24 (p<0.0001) and an overall response rate of 70% versus 22% over the 24-week double-blind period.
Sovleplenib received Orphan Drug Designation from the US FDA in October 2026 for primary ITP and autoimmune hemolytic anemia. HUTCHMED retains full worldwide rights to the drug.
- HUTCHMED (00013.HK): Presents HMPL-A830 Preclinical Data at ENA
- SIHUAN PHARM (00460.HK): bireociclib indication added to national NRDL
- HUTCHMED (00013.HK): Two of Three Drugs Add NRDL Indications
- HUTCHMED (00013.HK): Sovleplenib Wins FDA Orphan Drug Status for AIHA
- HUTCHMED (00013.HK): savolitinib+osimertinib filings accepted in Europe, Japan